PCV72 COST-EFFECTIVENESS OF EXTENDED-RELEASE NICOTINIC ACID/ LAROPIPRANT AS MONOTHERAPY VERSUS EZETIMIBE MONOTHERAPY IN PATIENTS WITH MIXED DYSLIPIDAEMIA IN SCOTLAND
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)72415-9
https://www.valueinhealthjournal.com/article/S1098-3015(11)72415-9/fulltext
Title :
PCV72 COST-EFFECTIVENESS OF EXTENDED-RELEASE NICOTINIC ACID/ LAROPIPRANT AS MONOTHERAPY VERSUS EZETIMIBE MONOTHERAPY IN PATIENTS WITH MIXED DYSLIPIDAEMIA IN SCOTLAND
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72415-9&doi=10.1016/S1098-3015(11)72415-9
First page :
A354
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
572